ClinicalTrials.gg
WithdrawnNCT03678480Updated Aug 12, 2026

A Study of HTD1801 in Adolescents With Primary Sclerosing Cholangitis (PSC)

A Phase 2 interventional study of HTD1801 and Ursodeoxycholic Acid in Primary Sclerosing Cholangitis, Cholangitis and Cholangitis, Sclerosing, sponsored by HighTide Therapeutics (Hong Kong) Limited. Withdrawn. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-08-12.

Sponsored by HighTide Therapeutics (Hong Kong) Limited · Phase 2, Interventional, and Treatment

Why this study was withdrawn
Corporate decision
Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
12 Years to 17 Years
Sex
All
01

Study summary

Randomized, double-blind, active-controlled, parallel-group study of HTD1801 in adolescents.

02

Conditions studied

  • Primary Sclerosing Cholangitis
  • Cholangitis
  • Cholangitis, Sclerosing
  • Bile Duct Diseases
  • Biliary Tract Diseases
  • Digestive System Diseases
  • Adolescent
03

In context

Cholangitis, Sclerosing

149 studies on the registry are indexed under Cholangitis, Sclerosing; 39 are open to participants now.

Browse Cholangitis, Sclerosing studies →

Lead sponsor

HighTide Therapeutics (Hong Kong) Limited is the lead sponsor of 8 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Weight ≥ 35 kg
  • Previous cholangiographic evidence of PSC by magnetic resonance cholangiopancreatography (MRCP) or direct cholangiography or liver findings
  • Serum GGT ≥ 2 × (ULN)
  • On a stable UDCA treatment regimen for ≥ 8 weeks

Exclusion criteria

Exclusion Criteria:

  • Secondary sclerosing cholangitis
  • Percutaneous or endoscopically-placed biliary drain or stent
  • History of cholangiocarcinoma or clinical suspicion of new dominant stricture within 1 year
  • Ascending cholangitis requiring intravenous antibiotic therapy within 60 days prior to Screening
  • Concomitant overlap syndrome with primary biliary cholangitis (PBC)
  • Significant hepatic decompensation
  • Alternative causes of chronic liver disease
  • Hospitalization for colitis within 30 days prior to Screening
  • Serum creatinine > 1.2 x
  • \< 10 g/dL
  • Glucose-6-phosphate dehydrogenase (G6PD) deficiency
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    HTD1801 500 mg BID (twice daily), or 1000 mg/day

    HTD1801 tablets in double-blind capsules, 250 mg

    Drug: HTD1801

  • Active comparator
    Ursodeoxycholic Acid (UDCA) 250 mg BID, or 500 mg/day

    UDCA tablets in double-blind capsules, 250 mg

    Drug: Ursodeoxycholic Acid

Interventions

06

What researchers measure

Primary outcomes

  1. change in gamma-glutamyl transferase (GGT)

    Time frame: 18 weeks

Secondary outcomes

  1. percentage of patients whose GGT normalizes to <50 units/liter

    Time frame: 18 weeks

  2. change in aspartate aminotransferase (AST)

    Time frame: 18 weeks

  3. change in alanine aminotransferase (ALT)

    Time frame: 18 weeks

  4. change in alkaline phosphatase (ALP)

    Time frame: 18 weeks

  5. change in total bilirubin

    Time frame: 18 weeks

  6. change in C-reactive protein (CRP)

    Time frame: 18 weeks

  7. incidence of adverse events

    Time frame: 18 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2021; primary completion for Oct 2021, 7 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2018
First posted
Sep 19, 2018
StartEst.
Mar 1, 2021
Primary completionEst.
Oct 4, 2021
CompletionEst.
Nov 4, 2021
Last update
Aug 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03678480
Lead sponsor
HighTide Therapeutics (Hong Kong) Limited
Responsible party
Sponsor
First posted
Sep 19, 2018
Start date
Mar 1, 2021 (estimated)
Primary completion
Oct 4, 2021 (estimated)
Completion
Nov 4, 2021 (estimated)
Last update
Aug 12, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Berberine ursodeoxycholate

Start the discussion